Marriage of imaging and genetics opens new view of brain function
Neuroimaging has revolutionized the study of the brain, but can provide no information about what is actually happening at molecular level in humans. Scientists at Yale have developed new approaches to link gene expression patterns to brain signals captured by imaging.
Anticevic, Murray edit new book on computational psychiatry
Alan Anticevic, PhD, Assistant Professor of Psychiatry and of Psychology, and John D. Murray, PhD, Assistant Professor of Psychiatry, have edited a new book that provides a comprehensive overview of the rapidly evolving field of computational psychiatry.
Beyond behavior: Frontiers of neuroscience research
Driven by scientific curiosity and humanitarian concern, clinical neuroscientist Alan Anticevic, PhD and other Yale researchers are trying to understand the mechanisms of the brain in a deeper, more systematic way for the benefit of people with mental health problems.
Waterbury Black church leaders, Yale team up to dispel myths about COVID vaccine for communities of color, seniors
In Waterbury, an aggressive effort to take the COVID-19 vaccine to hard-to-reach communities embarked on another chapter Friday. This time, one of the city’s most popular Black churches engaged in something unique to shatter some vaccine myths.Source: WTNH
Strategies to accelerate diagnosis and treatment of rare cardiovascular diseases
The current landscape for patients with rare cardiovascular disease has shifted. Using genome sequencing Yale physician-scientists have begun to elucidate the pathophysiology of genetic disorders and develop treatment guidelines and recommendations.
COVID-19: Being a part of research to make a change
Much like the rest of the world, I have been very aware of just how serious the COVID-19 pandemic is--a health crisis in need of immediate action with African Americans dying at twice the rate and hospitalized at almost three times that of our white counterparts. So, when I was given the opportunity to participate in the vaccine trial to fight the SARS-CoV-2 virus, I knew right away that it was my inherent duty as a community leader to sign up. As a Yale Cultural Ambassador and pastor for Walter’s Memorial AME Zion Church, it felt like such a significant way to further encourage members of my community to participate right alongside me, to drive health equity in our own community and advance science at the same time.
Bishop Kenneth Monroe: Prostate Cancer Survivor "Facing Uncertainty through Faith"
It was in the year 2000 when the Rev. Dr. Kenneth Monroe, then-pastor of the Metropolitan AME Zion Church, Hartford, CT noticed the need for more frequent bathroom breaks. Moreover, he realized that it was important to tell his doctor as soon as possible. He went for a physical and a prostate cancer screening which showed that his PSA count was 12.8. His doctor referred him to an urologist who ordered a prostate biopsy. The tissue was positive for cancer.
COVID-19: Making a Difference, Together
Vanessa Clayton’s story about clinical trials participation differs from most, as she was first approached to participate by her husband, Reverend Elvin Clayton, the pastor of the Walters Memorial AME Zion Church in Bridgeport, Connecticut and Cultural Ambassador to clinical research at Yale. Like many people of color, Mrs. Clayton was worried about the disproportionate impact of the COVID-19 virus on black and brown individuals. When her husband told her about the Phase 3 randomized and placebo-controlled trial looking to test the safety, tolerability, and immunogenicity of the SARS CoV 2 RNA vaccine against COVID-19, she did not immediately say yes. She decided to do her own homework to understand the research and also wanted to discuss it with family members in the health profession. Ultimately, after speaking to the study PI, Dr. Onyema Ogbuagu, and reviewing the informed consent, she decided to join her husband and hundreds of other Connecticut residents enrolling in the trial.
Tom Ficklin: Prostate Cancer Survivor "Remaining Calm in the Storm 'I Call it Thriving, Not Just Surviving'"
After a few years of slowly rising prostate specific antigen (PSA) counts, Tom Ficklin heard the words he was hoping he never would: “It’s time for a prostate biopsy.” Although the most important thing to Tom was his health and survival, he still wishes someone had discussed better pain management options with him before he had the biopsy. But when the results came back positive for cancer, his focus shifted to treatment options.
Yale-led Clinical Trial Offers Hope for COVID Patients and a Path Forward for Research
A new randomized study could reduce the morbidity and mortality associated with COVID-19 and streamline clinical research at Yale. The study will enroll 466 patients across five different Yale New Haven Hospital sites to identify a potential COVID-19 treatment.
'Healing' Stent on Par With Durable Polymer Stents: PIONEER III
A novel stent designed to target early wound healing met the primary noninferiority end point at 1 year in the PIONEER III trial, but differentiating itself from current high-performing durable-polymer drug-eluting stents (DES) will require more.Source: Medscape
Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) drug-eluting stent (DES), to the Xience or Promus Durable Polymer Drug-Eluting Stent (DP DES) showed it was equivalent in clinical performance to the market-leading DES.Source: Diagnostic and Interventional Cardiology
AHA 2020: PIONEER III trial: Drug-eluting stents are comparable
Prof. Alexandra Lansky presented the primary results of the PIONEER III trial, which aimed to demonstrate non-inferiority of the new HT-DES compared with the standard DP-DES, most commonly from XIENCE/Promus.Source: Physician's Weekly